These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 26364133)

  • 1. High-resolution genetic profile of viral genomes: why it matters.
    Qi H; Wu NC; Du Y; Wu TT; Sun R
    Curr Opin Virol; 2015 Oct; 14():62-70. PubMed ID: 26364133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing a low-cost drug resistance database for viral hepatitis.
    Kuiken C
    Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of HCV antiviral drug resistance.
    Welsch C; Zeuzem S
    Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
    Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
    Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of interferon resistance in hepatitis C virus.
    Perales C; Beach NM; Sheldon J; Domingo E
    Curr Opin Virol; 2014 Oct; 8():38-44. PubMed ID: 24968186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the HCV quasispecies and compartmentalization.
    Farci P
    Semin Liver Dis; 2011 Nov; 31(4):356-74. PubMed ID: 22189976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
    Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
    Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
    Welsch C
    Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.
    Hiraga N; Imamura M; Abe H; Hayes CN; Kono T; Onishi M; Tsuge M; Takahashi S; Ochi H; Iwao E; Kamiya N; Yamada I; Tateno C; Yoshizato K; Matsui H; Kanai A; Inaba T; Tanaka S; Chayama K
    Hepatology; 2011 Sep; 54(3):781-8. PubMed ID: 21626527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV genetic variability: from quasispecies evolution to genotype classification.
    Argentini C; Genovese D; Dettori S; Rapicetta M
    Future Microbiol; 2009 Apr; 4(3):359-73. PubMed ID: 19327119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).
    Kieffer TL; Kwong AD; Picchio GR
    J Antimicrob Chemother; 2010 Feb; 65(2):202-12. PubMed ID: 19903720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus Database and Bioinformatics Analysis Tools in the Virus Pathogen Resource (ViPR).
    Zhang Y; Zmasek C; Sun G; Larsen CN; Scheuermann RH
    Methods Mol Biol; 2019; 1911():47-69. PubMed ID: 30593617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular surveillance of hepatitis C.
    Khudyakov Y
    Antivir Ther; 2012; 17(7 Pt B):1465-70. PubMed ID: 23321496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.